

## REFERENCES

- Acton, D.S., Plat-Sinnige, M.J., van Wamel, W., de Groot, N. and van Belkum, A. (2009).** Intestinal carriage of *Staphylococcus aureus*: how does its frequency compare with that of nasal carriage and what is its clinical impact? *European Journal of Clinical Microbiology and Infectious Diseases*, **28**:115–127.
- Adem, P.V., Montgomery, C.P., Husain, A.N., Koogler, T.K., Arangelovich, V., Humilier, M., Boyle-Vavra, S. and Daum, R.S. (2005).** *Staphylococcus aureus* sepsis and the Waterhouse-Friderichsen syndrome in children. *The New England Journal of Medicine*, **353**:1245–1251.
- Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D.J. (1997).** Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Research*, **25**:3389-3402.
- Anderson, A.C. (2003).** The process of structure-based drug design. *Chemistry & Biology*, **10**:787–797.
- Anderson, S.D. and Gums, J.G. (2008).** Ceftobiprole: an extended-spectrum anti-methicillin-resistant *Staphylococcus aureus* cephalosporin. *The Annals of Pharmacotherapy*, **42**:806–816.
- Anishetty, S., Pulimi, M. and Pennathur, G. (2005).** Potential drug targets in *Mycobacterium tuberculosis* through metabolic pathway analysis. *Computational Biology and Chemistry*, **29**:368–378.
- Arbeit, R.D., Maki, D., Tally, F.P., Campanaro, E. and Eisenstein, B.I. (2004).** The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. *Clinical Infectious Diseases*. **38**:1673–1681.
- Baba, T., Takeuchi, F., Kuroda, M., Yuzawa, H., Aoki, K., Oguchi, A., Nagai, Y., Iwama, N., Asano, K., Naimi, T., Kuroda, H., Cui, L., Yamamoto, K. and Hiramatsu, K. (2002).** Genome and virulence determinants of high virulence community-acquired MRSA. *Lancet*, **359**:1819-1827.
- Bachmair, A., Finley, D. and Varshavsky, A. (1986).** *In vivo* half-life of a protein is a function of its amino-terminal residue. *Science*, **234**:179-186.
- Barber, M. (1961).** Methicillin-resistant staphylococci. *Journal of Clinical Pathology*, **14**:385-393.

**Barber, M. and Rozwadowska-Dowzenko, M. (1948).** Infection by penicillin-resistant staphylococci. *Lancet*, **2**:641–644.

**Bayer, A.S., Bolger, A.F., Taubert, K.A., Wilson, W., Steckelberg, J., Karchmer, A.W., Levison, M., Chambers, H.F., Dajani, A.S., Gewitz, M.H., Newburger, J.W., Gerber, M.A., Shulman, S.T., Pallasch, T.J., Gage, T.W. and Ferrieri, P. (1998).** Diagnosis and management of infective endocarditis and its complications. *Circulation*, **98**:2936–2948.

**Beam, J.W. and Buckley, B. (2006).** Community-Acquired Methicillin-Resistant *Staphylococcus aureus*: Prevalence and Risk Factors. *Journal of Athletic Training*, **41**:337-340.

**Berendsen, H.J.C., van der Spoel, D. and van Drunen, R. (1995).** GROMACS: A message-passing parallel molecular dynamics implementation. *Computer Physics Communications*, **91**:43-56.

**Beste, D.J., Hooper, T., Stewart, G., Bonde, B., Avignone-Rossa, C., Bushell, M.E., Wheeler, P., Klamt, S., Kierzek, A.M. and McFadden, J. (2007).** GSMN-TB: a web-based genome-scale network model of *Mycobacterium tuberculosis* metabolism. *Genome Biology*, **8**:R89.

**Böcher, S., Tønning, B., Skov, R.L. and Prag, J. (2009).** *Staphylococcus lugdunensis*, a common cause of skin and soft tissue infections in the community. *Journal of Clinical Microbiology*, **47**:946-950.

**Boucher, H.W. and Corey, G.R. (2008).** Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clinical Infectious Diseases*, **46**:S344–S349.

**Bowie, J.U., Lüthy, R. and Eisenberg, D. (1991).** A method to identify protein sequences that fold into a known three-dimensional structure. *Science*, **253**:164-170.

**Brown, D. and Superti-Furga, G. (2003).** Rediscovering the sweet spot in drug discovery, *Drug Discovery Today*, **8**:1067-1077.

**Brown, E.D., Vivas, E.I., Walsh, C.T. and Kolter, R. (1995).** MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in *Escherichia coli*. *Journal of Bacteriology*, **177**:4194-4197.

- Bucher, P. and Bairoch, A. (1994).** A generalized profile syntax for biomolecular sequence motifs and its function in automatic sequence interpretation. *Proceedings International Conference on Intelligent Systems Molecular Biology*, **2**:53-61.
- CDC (1999).** From the Centers for Disease Control and Prevention. Four pediatric deaths from community acquired methicillin-resistant *Staphylococcus aureus*--Minnesota and North Dakota, 1997–1999. *Journal of the American Medical Association*, **282**:1123–1125.
- CDC (2003).** Outbreaks of community-associated methicillin-resistant *Staphylococcus aureus* skin infections—Los Angeles County, California, 2002–2003. *Morbidity and Mortality Weekly Report*, **52**:88.
- Chambers, H.F. (2001).** The changing epidemiology of *Staphylococcus aureus*?. *Emerging Infectious Diseases*, **7**:178–182.
- Chambers, H.F. and DeLeo, F.R. (2009).** Waves of Resistance: *Staphylococcus aureus* in the antibiotic Era. *Nature Reviews Microbiology*, **7**:629–641.
- Chavali, A.K., D'Auria, K.M., Hewlett, E.L., Pearson, R.D. and Papin, J.A. (2012).** A metabolic network approach for the identification and prioritization of antimicrobial drug targets. *Trends in Microbiology*, **20**:113-123.
- Chen, S.Y., Wang, J.L., Chen, T.H., Chiang, W.C., Wang, J.T., Chen, S.C., Chang, S.C. and Hsueh, P.R. (2010).** Differences between methicillin-resistant *Staphylococcus aureus* bacteremic isolates harboring type IV and type V staphylococcal cassette chromosome mec genes based on prior patient healthcare exposure. *European Journal of Clinical Microbiology & Infectious Diseases*, **29**:1539-1546.
- Chhabra, G., Sharma, P., Anant, A., Deshmukh, S., Kaushik, H. Gopal, K., Srivastava, Sharma, N. and Garg L.C. (2010).** Identification and modeling of a drug target for *Clostridium perfringens* SM101. *Bioinformation*, **4**: 278-289.
- Christoph, F. (2001).** Novel computational methods in anti-microbial target identification. *Drug Discovery Today*, **6**:72-80.
- Chua, T., Moore, C.L., Perri, M.B., Donabedian, S.M., Masch, W., Vager, D., Davis, S.L., Lulek, K., Zimmnicki, B. and Zervos, M.J. (2008).** Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* bloodstream isolates in urban Detroit. *Journal of Clinical Microbiology*, **46**:2345–2352.

**Cole, A.M., Tahk, S., Oren, A., Yoshioka, D., Kim, Y.H., Park, A. and Ganz, T., (2001).** Determinants of *Staphylococcus aureus* nasal carriage. *Clinical and Diagnostic Laboratory Immunology*, **8**:1064–1069.

**Colovos, C. and Yeates, T.O. (1993).** Verification of protein structures: patterns of non-bonded atomic interactions. *Protein Science*, **2**:1511-1519.

**Cook, H.A., Furuya, E.Y., Larson, E., Vasquez, G. and Lowy, F.D. (2007).** Heterosexual transmission of community associated methicillin-resistant *Staphylococcus aureus*. *Clinical Infectious Diseases*, **44**:410–413.

**Cooper, S.J., Leonard, G.A., McSweeney, S.M., Thompson, A.W., Naismith, J.H., Qamar, S., Plater, A., Berry, A. and Hunter, W.N. (1996).** The crystal structure of a class II fructose-1,6-bisphosphate aldolase shows a novel binuclear metal-binding active site embedded in a familiar fold. *Structure*, **4**:1303-1315.

**Crum, N.F., Lee, R.U., Thornton, S.A., Stine, O.C., Wallace, M.R., Barrozo, C., Keefer-Norris, A., Judd, S. and Russell K.L. (2006).** Fifteen-year study of the changing epidemiology of methicillin-resistant *Staphylococcus aureus*. *American Journal of Medicine*, **119**:943–951.

**D'Souza, N., Rodrigues, C. and Mehta, A. (2010).** Molecular characterization of Methicillin-resistant *Staphylococcus aureus* with emergence of epidemic clones of sequence type (ST) 22 and ST 772 in Mumbai, India. *Journal of Clinical Microbiology*, **48**:1806–1811.

**David, M.Z. and Daum, R.S. (2010).** Community-Associated Methicillin-Resistant *Staphylococcus aureus*: Epidemiology and Clinical Consequences of an Emerging Epidemic. *Clinical Microbiology Reviews*, **23**:616–687.

**Davis, S.L., Perri, M.B., Donabedian, S.M., Manierski, C., Singh, A., Vager, D., Haque, N.Z., Speirs, K., Muder, R.R., Robinson-Dunn, B., Hayden, M.K. and Zervos, M.J. (2007).** Epidemiology and outcomes of community-associated methicillin-resistant *Staphylococcus aureus* infection. *Journal of Clinical Microbiology*, **45**:1705–1711.

**Desper, R. and Gascuel, O. (2004).** Theoretical foundation of the balanced minimum evolution method of phylogenetic inference and its relationship to weighted least-squares tree fitting. *Molecular Biology and Evolution*, **21**:587-598.

**Deurenberg, R.H. and Stobberingh, E.E. (2009).** The molecular evolution of hospital- and community-associated methicillin-resistant *Staphylococcus aureus*. *Current Molecular Medicine*, **9**:100-115.

- DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003).** The price of innovation: new estimates of drug development costs. *Journal of Health Economics*, **22**:151–185.
- Dombrowski, J.C. and Winston, L.G. (2008).** Clinical failures of appropriately-treated methicillin-resistant *Staphylococcus aureus* infections. *The Journal of Infection*, **57**:110–115.
- Du, W., Brown, J.R., Sylvester, D.R., Huang, J., Chalker, A.F., So C.Y., Holmes, D.J., Payne, D.J. and Wallis, N.G. (2000).** Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. *Journal of Bacteriology*, **182**:4146-4152.
- Ducati, R.G., Basso, L.A., Santos, D.S. and de Azevedo, W.F. Jr. (2010).** Crystallographic and docking studies of purine nucleoside phosphorylase from *Mycobacterium tuberculosis*. *Bioorganic Medicinal Chemistry*, **18**:4769–4774.
- Dutta, A., Singh, S.K., Ghosh, P., Mukherjee, R., Mitter, S. and Bandyopadhyay, D. (2006).** In silico identification of potential therapeutic targets in the human pathogen *Helicobacter pylori*. *In Silico Biology*, **6**:43-47.
- Fassy, F., Krebs, O., Lowinski, M., Ferrari, P., Winter, J., Collard-Dutilleul, V. and Salahbey, H.K. (2004).** UMP kinase from *Streptococcus pneumoniae*: evidence for cooperative ATP binding and allosteric regulation. *The Biochemical Journal*, **384**:619–627.
- Finn, R.D., Mistry, J., Tate, J., Coggill, P., Heger, A., Pollington, J.E., Gavin, O.L., Gunasekaran, P., Ceric, G., Forslund, K., Holm, L., Sonnhammer, E.L., Eddy, S.R. and Bateman, A. (2010).** The Pfam protein families database. *Nucleic Acids Research Database Issue*, **38**: 211-222.
- Fonvielle, M., Weber, P., Dabkowska, K. and Therisod, M. (2004).** New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases. *Bioorganic & Medicinal Chemistry Letters*, **14**:2923-2926.
- Fonvielle, M., Coinçon, M., Daher, R., Desbenoit, N., Kosieradzka, K., Barilone, N., Gicquel, B., Sygusch, J., Jackson, M. and Therisod, M. (2008).** Synthesis and biochemical evaluation of selective inhibitors of class II fructose bisphosphate aldolases: towards new synthetic antibiotics. *Chemistry*, **14**:8521-8529.
- Foster, J.M., Raverdy, S., Ganatra, M.B., Colussi, P.A., Taron, C.H. and Carlow, C.K. (2009).** The Wolbachia endosymbiont of *Brugia malayi* has an active phosphoglycerate mutase: a candidate target for anti-filarial therapies. *Parasitology Research*, **104**:1047-1052.

**Foster, T.J. (2005).** Immune evasion by staphylococci. *Nature Reviews Microbiology*, **3**:948–958.

**Foster, T.J. and Hook, M. (1998).** Surface protein adhesins of *Staphylococcus aureus*. *Trends in Microbiology*, **6**:484–488.

**Fowler, V.G. Jr., Boucher, H.W., Corey, G.R., Abrutyn, E., Karchmer, A.W., Rupp, M.E., Levine, D.P., Chambers, H.F., Tally, F.P., Vigliani, G.A., Cabell, C.H., Link, A.S., DeMeyer, I., Filler, S.G., Zervos, M., Cook, P., Parsonnet, J., Bernstein, J.M., Price, C.S., Forrest, G.N., Fätkenheuer, G., Gareca, M., Rehm, S.J., Brodt, H.R., Tice, A. and Cosgrove, S.E. (2006).** Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *The New England Journal of Medicine*, **355**:653–665.

**Fraunholz, M. and Sinha, B. (2012).** Intracellular *Staphylococcus aureus*: live-in and let die. *Frontiers in Cellular and Infection Microbiology*, **2**:43.

**Freiberg, C. (2001).** Novel computational methods in anti-microbial target identification. *Drug Discovery Today*, **6**:S72-80.

**Fridkin, S.K., Hageman, J.C., Morrison, M., Sanza, L.T., Como-Sabetti, K., Jernigan, J.A., Harriman, K., Harrison, L.H., Lynfield, R. and Farley, M.M. (2005).** Methicillin-resistant *Staphylococcus aureus* disease in three communities. *The New England Journal of Medicine*, **352**:1436–1444.

**Galkin, A., Kulakova, L., Melamud, E., Li, L., Wu, C., Mariano, P., Dunaway-Mariano, D., Nash, T. E. and Herzberg, O. (2007).** Characterization, Kinetics, and Crystal Structures of Fructose-1,6- bisphosphate Aldolase from the Human Parasite *Giardia lamblia*. *The Journal of Biological Chemistry*, **282**:4859–4867.

**Garnier, J., Osguthrope, D.J. and Robson, B. (1978).** Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. *Journal of Molecular Biology*, **130**: 97-120.

**Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M.R., Appel, R.D. and Bairoch A. (2005).** *Protein Identification and Analysis Tools on the ExPASy Server*, (In) John M. Walker (ed): *The Proteomics Protocols Handbook*, Humana Press, pp. 571-607.

**Gefflaut, T., Blonski, C., Perie, J. and Willson, M. (1995).** Class I aldolases: substrate specificity, mechanism, inhibitors and structural aspects. *Progress in Biophysics and Molecular Biology*, **63**:301-340.

**Gerhard, K. (2000).** Recent developments in structure-based drug design. *Journal of Molecular Medicine*, **78**:269–281.

**Gladstone, G.P. and VanHeyningen, W.E. (1957).** Staphylococcal leucocidins. *British Journal of Experimental Pathology*, **38**:123–137.

**Gold, H.S. and Moellering, R.C. Jr. (1996).** Antimicrobial-drug resistance. *The New England Journal of Medicine*, **335**:1445–1453.

**Gonzalez, B.E., Hulten, K.G., Dishop, M.K., Lamberth, L.B., Hammerman, W.A., Mason, E.O. Jr. and Kaplan, S.L. (2005a).** Pulmonary manifestations in children with invasive community-acquired *Staphylococcus aureus* infection. *Clinical Infectious Diseases*, **41**:583–590.

**Gonzalez, B.E., Martinez-Aguilar, G., Hulten, K.G., Hammerman, W.A., Coss-Bu, J., Avalos-Mishaan, A., Mason, E.O. Jr. and Kaplan, S.L. (2005b).** Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant *Staphylococcus aureus*. *Pediatrics*. **115**:642–648.

**Gonzalez, B.E., Rueda, A.M., Shelburne, S.A. III, Musher, D.M., Hamill, R.J. and Hulten, K.G. (2006).** Community associated strains of methicillin-resistant *Staphylococcus aureus* as the cause of healthcare associated infection. *Infection Control and Hospital Epidemiology*, **27**:1051–1056.

**Gopalakrishnan, R. and Sureshkumar, D. (2010).** Changing trends in antimicrobial susceptibility and hospital acquired infections over an 8 year period in a tertiary care hospital in relation to introduction of an infection control programme. *Journal of the Association of Physicians of India*. **58**:25–31.

**Gordon, R.J. and Lowy, F.D. (2008).** Pathogenesis of methicillin-resistant *Staphylococcus aureus* infection. *Clinical Infectious Diseases*, **46**:S350–S359.

**Gorwitz, R.J., Jernigan, D.B., Powers, J.H. and Jernigan, J.A. (2006).** Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention ([http://www.cdc.gov/ncidod/dhqp/ar\\_mrsa\\_ca.html](http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html)).

**Gorwitz, R.J., Kruszon-Moran, D., McAllister, S.K., McQuillan, G., McDougal, L.K., Fosheim, G.E., Jensen, B.J., Killgore, G., Tenover, F.C. and Kuehnert, M.J. (2008).** Changes in the prevalence of nasal colonization with *Staphylococcus aureus* in the United States, 2001–2004. *Journal of Infectious Diseases*, **197**:1226–1234.

**Grishin, N.V. (1999).** A novel approach to phylogeny reconstruction from protein sequences. *Journal of Molecular Evolution*, **48**:264-273.

**Grundmann, H., Aires-de-Sousa, M., Boyce, J. and Tiemersma, E.J. (2006).** Emergence and resurgence of methicillin resistant *Staphylococcus aureus* as a public-health threat. *Lancet*. **368**:874–885.

**Guex, N. and Peitsch, M.C. (1997).** SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis*, **18**:2714-2723.

**Guinan, M.E., Dan, B.B., Guidotti, R.J., Reingold, A.L., Schmid, G.P., Bettoli, E.J., Lossick, J.G., Shands, K.N., Kramer, M.A., Hargrett, N.T., Anderson, R.L. and Broome, C.V. (1982).** Vaginal colonization with *Staphylococcus aureus* in healthy women: a review of four studies. *Annals of Internal Medicine*, **96**:944–947.

**Guruprasad, K., Reddy, B.V.B. and Pandit, M.W. (1990).** Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting *in vivo* stability of a protein from its primary sequence. *Protein Engineering*, **4**:155-161.

**Haag, N.L., Velk, K.K. and Wu, C. (2011).** *In silico* Identification of Drug Targets in Methicillin/Multidrug-Resistant *Staphylococcus aureus*. Proceedings Third International Conference on Bioinformatics, Biocomputational Systems and Biotechnologies, BIOTECHNO 2011. IARIA XPS Press; Venice, Italy: May 22-27, 2011. pp. 91–99.

**Hari Prasad, O., Nanda Kumar, Y., Reddy, O.V., Chaudhary, A. and Sarma PV (2012).** Cloning, expression, purification and characterization of UMP kinase from *Staphylococcus aureus*. *The Protein Journal*, **31**:345-352.

**Herold, B.C., Immergluck, L.C., Maranan, M.C., Lauderdale, D.S., Gaskin, R.E., Boyle-Vavra, S., Leitch, C.D. and Daum, R.S. (1998).** Community-acquired methicillin-resistant *Staphylococcus aureus* in children with no identified predisposing risk. *Journal of the American Medical Association*, **279**:593–598.

**Hou, Q.M., Liu, X., Brostromer, E., Li, L.F. and Su, X.D. (2009).** Preliminary crystallographic studies of purine nucleoside phosphorylase from the cariogenic pathogen *Streptococcus mutans*. *Acta Crystallographica Section F: Structural Biology and Crystallization Communications*, **F65**:1289–1291.

**Hsiao, T.L., Revelles, O., Chen, L., Sauer, U. and Vitkup, D. (2010).** Automatic policing of biochemical annotations using genomic correlations. *Nature Chemical Biology*, **6**:34–40

**Huang, B. (2009).** metaPocket: a meta approach to improve protein ligand binding site prediction. *Omics*, **13**:325-330.

**Huang, H., Flynn, N.M., King, J.H., Monchaud, C., Morita, M. and Cohen, S.H. (2006).** Comparisons of community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) and hospital-associated MSRA infections in Sacramento, California. *Journal of Clinical Microbiology*, **44**:2423-2427.

**Ideker, T., Thorsson, V., Ranish, J.A., Christmas, R., Buhler, J., Eng, J.K., Bumgarner, R., Goodlett, D.R., Aebersold, R. and Hood, L. (2001).** Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. *Science*, **292**:929–934.

**Ikai, A.J. (1980).** Thermostability and aliphatic index of globular proteins. *Journal of Biochemistry*, **88**:1895-1898.

**INSAR (2013).** Methicillin resistant *Staphylococcus aureus* (MRSA) in India: prevalence and susceptibility pattern. *Indian Journal of Medical Research*, **137**:363-369.

**Irwin, J.J. and Shoichet, B.K. (2005).** ZINC-a free database of commercially available compounds for virtual screening. *Journal of Chemical Information and Modeling*, **45**:177-182.

**Ito, T. and Hiramatsu, K. (2003).** MRSA (methicillin-resistant *Staphylococcus aureus*). *Nippon Rinsho*, **61**:164–170.

**Jin, B.S., Han, S.G., Lee, W.K., Ryoo, S.W., Lee, S.J., Suh, S.W. and Yu, Y.G. (2009).** Inhibitory Mechanism of Novel Inhibitors of UDP-N-Acetylglucosamine Enolpyruvyl Transferase from *Haemophilus influenzae*. *Journal of Microbiology and Biotechnology*, **19**:1582–1589.

**Jorgensen, W.L. (2004).** The many roles of computation in drug discovery. *Science*, **303**:1813–1818.

**Kanehisa, M., Goto, S., Kawashima, S. and Nakaya, A. (2002).** The KEGG databases at GenomeNet. *Nucleic Acids Research*, **30**:42–46.

**Kaplan, S.L., Hulten, K.G., Gonzalez, B.E., Hammerman, W.A., Lamberth, L., Versalovic, J. and Mason, E.O. Jr. (2005).** Three-year surveillance of community-acquired *Staphylococcus aureus* infections in children. *Clinical Infectious Diseases*, **40**:1785–1791.

**Kazakova, S.V., Hageman, J.C., Matava, M., Srinivasan, A., Phelan, L., Garfinkel, B., Boo, T., McAllister, S., Anderson, J., Jensen, B., Dodson, D., Lonsway, D., McDougal, L.K., Arduino, M., Fraser, V.J., Killgore, G., Tenover, F.C., Cody, S. and Jernigan, D.B. (2005).** A clone of methicillin-resistant *Staphylococcus aureus* among professional football players. *The New England Journal of Medicine*, **352**:468–475.

**Khatib, R., Johnson, L.B., Sharma, M., Fakih, M.G., Ganga, R. and Riederer, K. (2009).** Persistent *Staphylococcus aureus* bacteremia: Incidence and outcome trends over time. *Scandinavian Journal of Infectious Diseases*, **41**:4–9.

**Klein, E., Smith, D.L. and Laxminarayan, R. (2007).** Hospitalizations and deaths caused by methicillin resistant *Staphylococcus aureus*, United States, 1999–2005. *Emerging Infectious Diseases*, **12**:1840–1846.

**Klevens, R.M., Morrison, M.A., Nadle, J., Petit, S., Gershman, K., Ray, S., Harrison, L.H., Lynfield, R., Dumyati, G., Townes, J.M., Craig, A.S., Zell, E.R., Fosheim, G.E., McDougal, L.K., Carey, R.B. and Fridkin, S.K. (2007).** Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *Journal of the American Medical Association*, **298**:1763–1771.

**Kloczkowski, A., Ting, K.L., Jernigan, R.L. and Garnier, J. (2002).** Combining the GOR V algorithm with evolutionary information for protein secondary structure prediction from amino acid sequence. *Proteins*, **49**:154–166.

**Kluytmans, J. and Struelens, M. (2009).** Methicillin resistant *Staphylococcus aureus* in the hospital. *British Medical Journal*, **338**:b364–b369.

**Kluytmans, J., van Belkum, A. and Verbrugh, H. (1997).** Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clinical microbiology reviews*, **10**:505–520.

**Kluytmans-Vandenbergh, M.F. and Kluytmans, J.A. (2006).** Community-acquired methicillin-resistant *Staphylococcus aureus*: Current perspectives. *Clinical Microbiology and Infection*, **12**:9–15.

**Koga, T., Abe, T., Inoue, H., Takenouchi, T., Kitayama, A., Yoshida, T., Masuda, N., Sugihara, C., Kakuta, M., Nakagawa, M., Shibayama, T., Matsushita, Y., Hirota, T., Ohya, S., Utsui, Y., Fukuoka, T. and Kuwahara, S. (2005).** *In vitro* and *in vivo* antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. *Antimicrobial Agents and Chemotherapy*, **49**:3239–3250.

**Korzeniowski, O. and Sande, M.A. (1982).** Combination antimicrobial therapy for *Staphylococcus aureus* endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. *Annals of Internal Medicine*, **97**:496–503.

**Kravitz, G.R., Dries, D.J., Peterson, M.L. and Schlievert, P.M. (2005).** Purpura fulminans due to *Staphylococcus aureus*. *Clinical Infectious Diseases*, **40**:941–947.

**Kuhn, M., Szklarczyk, D., Franceschini, A., von Mering, C., Jensen, L.J., Bork, P. (2012).** STITCH 3: zooming in on protein-chemical interactions. *Nucleic Acids Research*, **40**:D876-880.

**Kurlendal, J. and Grinholc, M. (2012).** Alternative therapies in *Staphylococcus aureus* diseases. *Acta Biochimica Polonica*, **59**:1-14.

**Kyte, J. and Doolittle, R.F. (1982).** A simple method for displaying the hydrophobic character of a protein. *Journal of Molecular Biology*, **157**:105-132.

**Lacey, R.W. (1984).** Mechanisms of resistance to beta-lactam antibiotics in *Staphylococcus aureus*. *Scandinavian Journal of Infectious Diseases Supplementum*, **42**:64-71.

**Larsen, A.R., Stegger, M., Böcher, S., Sørum, M., Monnet, D.L. and Skov, R.L. (2009).** Emergence and characterization of community-associated methicillin-resistant *Staphylococcus aureus* infections in Denmark, 1999 to 2006. *Journal of Clinical Microbiology*, **47**:73–78.

**Laskowski, R.A. and Swindells, M.B. (2011).** LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *Journal of Chemical Information and Modeling*, **51**:2778-2786.

**Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thornton, J.M. (1993).** PROCHECK: a program to check the stereochemical quality of protein structures. *Journal of Applied Crystallography*, **26**:283–291.

**Laupland, K.B., Ross, T. and Gregson, D.B. (2008).** *Staphylococcus aureus* bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. *Journal of Infectious Diseases*, **198**:336–343.

**Lee, M.C., Rios, A.M., Aten, M.F., Mejias, A., Cavuoti, D., McCracken, G.H. Jr. and Hardy, R.D. (2004).** Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant *Staphylococcus aureus*. *The Pediatric Infectious Disease Journal*, **23**:123–127.

**Lee, S.K., Lee, I.H., Kim, H.J., Chang, G.S., Chung, J.E. and No, K.T. (2003).** The PreADME approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties, *EuroQSAR 2002 Designing Drugs and Crop Protectants: Processes, Problems and Solutions*, Blackwell Publishing, Malden, MA, pp. 418–420.

**Lina, G., Piémont, Y., Godail-Gamot, F., Bes, M., Peter, M.O., Gauduchon, V., Vandenesch, F. and Etienne, J. (1999).** Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clinical Infectious Diseases*, **29**:1128–1132.

**Linding, R., Russell, R.B., Neduva, V. and Gibson, T.J. (2003).** GlobPlot: Exploring protein sequences for globularity and disorder. *Nucleic Acids Research*, **31**:3701-3708.

**Llera, J.L. and Levy, R.C. (1985).** Treatment of cutaneous abscess: a double-blind clinical study. *Annals of Emerging Medicine*, **14**:15–19.

**Lodise, T.P., Lomaestro, B., Graves, J. and Drusano, G.L. (2008).** Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. *Antimicrobial Agents and Chemotherapy*, **52**:1330–1336.

**Lowy, F.D. (1998).** *Staphylococcus aureus* infections. *The New England Journal of Medicine*, **339**:520–532.

**Ma, X.L., Chen, C. and Yang J. (2005).** Predictive model of blood-brain barrier penetration of organic compounds. *Acta Pharmacologica Sinica*, **26**:500-512.

**Marchler-Bauer, A., Marchler-Bauer, A., Lu, S., Anderson, J.B., Chitsaz, F., Derbyshire, M.K., DeWeese-Scott, C., Fong, J.H., Geer, L.Y., Geer, R.C., Gonzales, N.R., Gwadz, M., Hurwitz, D.I., Jackson, J.D., Ke, Z., Lanczycki, C.J., Lu, F., Marchler, G.H., Mullokandov, M., Omelchenko, M.V., Robertson, C.L., Song, J.S., Thanki, N., Yamashita, R.A., Zhang, D., Zhang, N., Zheng, C. and Bryant, S.H. (2011).** CDD: a Conserved Domain Database for the functional annotation of proteins. *Nucleic Acids Research*, **39**:D225-D229.

**Marcotte, E.M., Pellegrini, M., Thompson, M.J., Yeates, T.O. and Eisenberg, D. (1999).** A combined algorithm for genome-wide prediction of protein function. *Nature*, **402**:83–86.

**Martinez, J.L. (2008).** Antibiotics and antibiotic resistance genes in natural environments. *Science*. **321**:365-367.

- McDougal, L.K., Steward, C.D., Killgore, G.E., Chaitram, J.M., McAllister, S.K. and Tenover, F.C. (2003).** Pulsed-field gel electrophoresis typing of oxacillin-resistant *Staphylococcus aureus* isolates from the United States: establishing a national database. *Journal of Clinical Microbiology*, **41**:5113–5120.
- Meng, E.C., Shoichet, B.K. and Kuntz, I.D. (1992).** Automated Docking with Grid-Based Energy Evaluation. *Journal of Computational Chemistry*, **13**:505-524.
- Miles, E.W., Kawasaki, H., Ahmed, S.A., Morita, H., Morita, H. and Nagata, S. (1989).** The  $\beta$ -subunit of Tryptophan Synthase. Clarification of the roles of histidine 86, lysine 87, cysteine 170 and cysteine 230. *Journal Biological Chemistry*, **264**:6280-6287.
- Miller, L.G., Perdreau-Remington, F., Rieg, G., Mehdi, S., Perlroth, J., Bayer, A.S., Tang, A.W., Phung, T.O. and Spellberg, B. (2005).** Necrotizing fasciitis caused by community-associated methicillin-resistant *Staphylococcus aureus* in Los Angeles. *The New England Journal of Medicine*, **352**:1445–1453.
- MMWR (1999).** Four pediatric deaths from community-acquired methicillin-resistant *Staphylococcus aureus*-Minnesota and North Dakota, 1997–1999. *Morbidity and Mortality Weekly Report*, **48**:707–710.
- MMWR (2003).** Methicillin-resistant *Staphylococcus aureus* infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles county, 2000–2003. *Morbidity and Mortality Weekly Report*, **52**:793–795.
- Moir, D.T., Shaw, K.J., Hare, R.S. and Vovis, G.F. (1999).** Genomics and antimicrobial drug discovery. *Antimicrobial Agents and Chemotherapy*, **43**:439-446.
- Monaco, M., Antonucci, R., Palange, P., Venditti, M. and Pantosti, A. (2005).** Methicillin-resistant *Staphylococcus aureus* necrotizing pneumonia. *Emerging Infectious Diseases*, **11**:1647–1648.
- Moran, G.J., Krishnadasan, A., Gorwitz, R.J., Fosheim, G.E., McDougal, L.K., Carey, R.B. and Talan, D.A. (2006).** Methicillin-resistant *S. aureus* infections among patients in the emergency department. *The New England Journal of Medicine*, **355**:666–674.
- Moreillon, P., Que, Y.A. and Bayer, A.S. (2000).** Pathogenesis of streptococcal and staphylococcal endocarditis. *Infectious Disease Clinics of North America*, **16**:297–318.

- Morell, E.A. and Balkin, D.M. (2010).** Methicillin-resistant *Staphylococcus aureus*: a pervasive pathogen highlights the need for new antimicrobial development. *The Yale Journal of Biology and Medicine*, **83**:223-233.
- Morris, G.M., David, S.G., Robert, S.H., Ruth, H., William, E.H., Richard, K.B. and Arthur, J.O. (1998).** Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, *Journal of Computational Chemistry*, **19**:1639–1662.
- Moss, B., Squire, J.R. and Topley, E. (1948).** Nose and skin carriage of *Staphylococcus aureus* in patients receiving penicillin. *Lancet*, **1**:320–325.
- Mostofsky, E., Lipsitch, M. and Regev-Yochay, G. (2011).** Is methicillin-resistant *Staphylococcus aureus* replacing methicillin-susceptible *S. aureus*? *Journal of Antimicrobial Chemotherapy*, **66**:2199-2214.
- Nathwani, D., Morgan, M., Masterton, R.G., Dryden, M., Cookson, B.D., French, G. and Lewis, D. (2008).** Guidelines for UK practice for the diagnosis and management of methicillin resistant *Staphylococcus aureus* (MRSA) infections presenting in the community. *Journal of Antimicrobial Chemotherapy*, **61**:976–994.
- Nimmo, G.R. and Coombs, G.W. (2008).** Community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) in Australia. *International Journal of Antimicrobial Agents*, **31**:401–410.
- Nissen, P., Hansen, J., Ban, N., Moore, P. and Steitz, T. (2000).** The structural basis of ribosome activity in peptide bond synthesis. *Science*, **289**:920–930.
- Oberhardt, M.A., Palsson, B.Ø. and Papin, J.A. (2009).** Applications of genome-scale metabolic reconstructions. *Molecular Systems Biology*, **5**:320.
- Ogawa, S.K., Yurberg, E.R., Hatcher, V.B., Levitt, M.A. and Lowy, F.D. (1985).** Bacterial adherence to human endothelial cells *in vitro*. *Infection and Immunity*, **50**:218–224.
- Ogston, A. (1984).** Classics in Infectious Diseases. "On abscesses". *Reviews of Infectious Diseases*, **6**:122–128.
- Otter, J.A. and French, G.L. (2006).** Nosocomial transmission of community-associated methicillin-resistant *Staphylococcus aureus*: An emerging threat. *Lancet Infectious Diseases*, **6**:753–755.
- Otto, M. (2010).** Looking toward basic science for potential drug discovery targets against community-associated MRSA. *Medical Research Reviews*, **30**:1–22.

- Pan, A., Lorenzotti, S. and Zoncada, A. (2008).** Registered and investigational drugs for the treatment of methicillin-resistant *Staphylococcus aureus* infection. *Recent Patents on Anti-Infective Drug Discovery*, **3**:10–33.
- Papadopoulos, J.S. and Agarwala, R. (2007).** COBALT: constraint-based alignment tool for multiple protein sequences. *Bioinformatics*, **23**:1073-1079.
- Parish, D. and Scheinfeld, N. (2008).** Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. *Current Opinion in Investigational Drugs*, **9**:201–209.
- Patel, A.K., Patel, K.K., Patel, K.R., Shah, S. and Dileep, P. (2010).** Time trends in the epidemiology of microbial infections at a tertiary care center in west India over last 5 years. *Journal of the Association of Physicians of India*, **58**:37–40.
- Patti, J.M., Allen, B.L., McGavin, M.J. and Hook, M. (1994).** MSCRAMM-mediated adherence of microorganisms to host tissues. *Annual Review of Microbiology*, **48**:585–617.
- Pawson, T. and Nash, P. (2003).** Assembly of cell regulatory systems through protein interaction domains. *Science*, **300**:445–452.
- Pegan, S.D., Rukserree, K., Franzblau, S.G. and Mesecar, A.D. (2009).** Structural basis for catalysis of a tetrameric, class IIa *fructose* 1,6-bisphosphate aldolase from *M. tuberculosis*. *Journal of Molecular Biology*, **386**:1038–1053.
- Pellegrini, M., Marcotte, E.M., Thompson, M.J., Eisenberg, D. and Yeates, T.O. (1999).** Assigning protein functions by comparative genome analysis: protein phylogenetic profiles. *Proceedings of the National Academy of Sciences USA*, **96**:4285–4288.
- Persidis, A. (1998).** Signal Transduction as a drug-discovery platform. *Nature Biotechnology*, **16**:1082–1083.
- Perumal, D., Lim, C.S., Sakharkar, K.R. and Sakharkar, M.K. (2007).** Differential genome analyses of metabolic enzymes in *Pseudomonas aeruginosa* for drug target identification. *In Silico Biology*, **7**:453-465.
- Popovich, K.J., Weinstein, R.A. and Hota, B. (2008).** Are community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) strains replacing traditional nosocomial MRSA strains? *Clinical Infectious Diseases*, **46**:795–798.
- Powell, J.P. and Wenzel, R.P. (2008).** Antibiotic options for treating community-acquired MRSA. *Expert Review of Anti-infective Therapy*, **6**:299-307.

- Proctor, R.A., van Langevelde, P., Kristjansson, M., Maslow, J.N. and Arbeit, R.D. (1995).** Persistent and relapsing infections associated with small-colony variants of *Staphylococcus aureus*. *Clinical Infectious Diseases*, **20**:95–102.
- Ramachandran, G.N. and Sasisekharan, V. (1968).** Conformation of polypeptides and proteins. *Advances in Protein Chemistry*, **23**: 283–437.
- Rayan, K.J. (2004).** Nosocomial infections and infection control. In: Ryan KJ, Ray CG (editors). *Sherris Medical Microbiology: an introduction to infectious diseases*. **4th ed.** New York: McGraw-Hill Medical Publishing Division: pp. 915-921.
- Reddy, M.R. and Erion, M.D. (1998).** Structure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors. *Journal of Enzyme Inhibitor*, **14**:1-14.
- Ren, K., Bannan, J.D., Pancholi, V., Cheung, A.L., Robbins, J.C., Fischetti, V.A. and Zabriskie, J.B. (1994).** Characterization and biological properties of a new staphylococcal exotoxin. *The Journal of Experimental Medicine*, **180**:1675–1683.
- Rodaki, A., Young, T. and Brown, A.J. (2006).** Effects of Depleting the Essential Central Metabolic Enzyme Fructose-1,6-Bisphosphate Aldolase on the Growth and Viability of *Candida albicans*: Implications for Antifungal Drug Target Discovery. *Eukaryotic Cell*, **5**:1371-1377.
- Rollason, J., Bastin, L., Hilton, A.C., Pillay, D.G., Worthington, T., McKeon, C., De, P., Burrows, K. and Lambert, P.A. (2008).** Epidemiology of community-acquired methicillin-resistant *Staphylococcus aureus* obtained from the UK West Midlands region. *Journal of Hospital Infection*, **70**:314–320.
- Ruiz, M.E., Yohannes, S. and Wladyka, C.G. (2005).** Pyomyositis caused by methicillin-resistant *Staphylococcus aureus*. *The New England Journal of Medicine*, **352**:1488–1489.
- Rupp, M.E., Soper, D.E. and Archer, G.L. (1992).** Colonization of the female genital tract with *Staphylococcus saprophyticus*. *Journal of Clinical Microbiology*, **30**:2975-2979.
- Rutar, T., Chambers, H.F., Crawford, J.B., Perdreau-Remington, F., Zwick, O.M., Karr, M., Diehn, J.J. and Cockerham, K.P. (2006).** Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant *Staphylococcus aureus*. *Ophthalmology*, **113**:1455–1462.

- Saiman, L., O'Keefe, M., Graham, P.L., Wu, F., Saïd-Salim, B., Kreiswirth, B., LaSala, A., Schlievert, P.M. and Della-Latta, P. (2003).** Hospital transmission of community-acquired methicillin-resistant *Staphylococcus aureus* among postpartum women. *Clinical Infectious Diseases*, **37**:1313–1319.
- Salyers, A.A. and Amabile-Cuevas, C.F. (1997).** Why are antibiotic resistance genes so resistant to elimination? *Antimicrobial Agents and Chemotherapy*, **41**:2321–2325.
- Saravolatz, L.D., Markowitz, N., Arking, L., Pohlod, D. and Fisher, E. (1982).** Methicillin-resistant *Staphylococcus aureus*. Epidemiologic observations during a community-acquired outbreak. *Annals of Internal Medicine*, **96**:11–16.
- Schoichet, B. K. and Kuntz, I. D. (1993).** Matching chemistry and shape in molecular docking. *Protein Engineering*, **6**:723-732.
- Selick, H.E., Beresford, A.P. and Tarbit, M.H. (2002).** The emerging importance of predictive ADME simulation in drug discovery. *Drug Discovery Today*, **7**:109-116.
- Senn, L., Basset, P., Nahimana, I., Zanetti, G. and Blanc, D.S. (2012).** Which anatomical sites should be sampled for screening of methicillin-resistant *Staphylococcus aureus* carriage by culture or by rapid PCR test? *Clinical Microbiology and Infection*, **18**:E31–E33.
- Seybold, U., Kourbatova, E.V., Johnson, J.G., Halvosa, S.J., Wang, Y.F., King, M.D., Ray, S.M. and Blumberg, H.M. (2006).** Emergence of community-associated methicillin resistant *Staphylococcus aureus* USA300 genotype as a major cause of health care-associated blood stream infections. *Clinical Infectious Diseases*, **42**:647–656.
- Sharma, V., Gupta, P. and Dixit, A. (2008).** *In silico* identification of putative drug targets from different metabolic pathways of *Aeromonas hydrophila*. *In Silico Biology*, **8**:331-337.
- Shen, H., Yang, Y., Wang, F., Zhang, Y., Ye, N., Xu, S. and Wang, H. (2009).** Characterization of the putative tryptophan synthase b-subunit from *Mycobacterium tuberculosis*. *Acta Biochimica et Biophysica Sinica*, **41**:379-388.
- Shorr, A.F., Kunkel, M.J. and Kollef, M. (2005).** Linezolid versus vancomycin for *Staphylococcus aureus* bacteraemia: pooled analysis of randomized studies. *Journal of Antimicrobial Chemotherapy*, **56**:923–929.
- Sifri, C.D., Park, J., Helm, G.A., Stemper, M.E. and Shukla, S.K. (2007).** Fatal brain abscess due to community associated methicillin-resistant *Staphylococcus aureus* strain USA300. *Clinical Infectious Diseases*, **45**:e113–e117.

- Singer, M., Rossmiese, P., Cali, B.M., Liebke, H. and Gross, C.A. (1991).** The *Escherichia coli* ts8 mutation is an allele of *fda*, the gene encoding fructose-1,6-diphosphate aldolase. *Journal of Bacteriology*, **173**:6242–6248.
- Soding, J., Biegert, A. and Lupas, A.N. (2005).** The HHpred interactive server for protein homology detection and structure prediction. *Nucleic Acids Research*, **33**: W244-W248.
- Sollid, J.U.E., Furberg, A.S., Hanssen, A.M. and Johannessen, M. (2013).** *Staphylococcus aureus*: Determinants of human carriage. *Infection, Genetics and Evolution* (In press).
- Steinkraus, G., White, R. and Friedrich, L. (2007).** Vancomycin MIC creep in non-vancomycin-intermediate *Staphylococcus aureus* (VISA), vancomycin-susceptible clinical methicillin-resistant *S. aureus* (MRSA) blood isolates from 2001–05. *Journal of Antimicrobial Chemotherapy*, **60**:788–794.
- Swartz, M.N. (1994).** Hospital-acquired infections: diseases with increasingly limited therapies. *Proceedings of the National Academy of Sciences USA*, **91**:2420–2427.
- Szappanos, B., Kovács, K., Szamecz, B., Honti, F., Costanzo, M., Baryshnikova, A., Gelius-Dietrich, G., Lercher, M.J., Jelasity, M., Myers, C.L., Andrews, B.J., Boone, C., Oliver, S.G., Pál, C. and Papp, B. (2011).** An integrated approach to characterize genetic interaction networks in yeast metabolism. *Nature Genetics*, **43**:656–662.
- Tang, Y., Zhu, W., Chen, K. and Jiang, H. (2006).** New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery. *Drug Discovery Today: Technologies*, **3**:307-313.
- Tielens, A.G., van Grinsven, K.W., Henze, K., van Hellemond, J.J. and Martin, W. (2010).** Acetate formation in the energy metabolism of parasitic helminths and protists. *International Journal of Parasitology*, **40**:387-397.
- Trott, O. and Olson, A.J. (2010).** AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*, **31**:455-461.
- Tzianabos, A.O., Wang, J.Y. and Lee, J.C. (2001).** Structural rationale for the modulation of abscess formation by *Staphylococcus aureus* capsular polysaccharides. *Proceedings of the National Academy of Sciences USA*, **98**:9365–9370.
- Udo, E.E., Pearman, J.W. and Grubb, W.B. (1993).** Genetic analysis of community isolates of methicillin-resistant *Staphylococcus aureus* in western Australia. *Journal of Hospital Infection*, **25**:97–108.

**van Gunsteren, W.F., Billeter, S.R., Eising, A.A., Hünenberger, P.H., Krüger, P., Mark, A. E., Scott, W.R.P. and Tironiet I.G. (1996).** Biomolecular simulation: the GROMOS96 manual and user guide. Vdf Hochschulverlag ETH Zurich, Switzerland, pp. 1-1042.

**Vandenesch, F., Naimi, T., Enright, M.C., Lina, G., Nimmo, G.R., Heffernan, H., Liassine, N., Bes, M., Greenland, T., Reverdy, M.E. and Etienne, J. (2003).** Community-acquired methicillin-resistant *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes: worldwide emergence. *Emerging Infectious Diseases*, **9**:978–984.

**von Eiff, C., Becker, K., Machka, K., Stammer, H. and Peters, G. (2001).** Nasal carriage as a source of *Staphylococcus aureus* bacteremia. *The New England Journal of Medicine*, **344**:11–16.

**Voyich, J.M., Braughton, K.R., Sturdevant, D.E., Whitney, A.R., Said-Salim, B., Porcella, S.F., Long, R.D., Dorward, D.W., Gardner, D.J., Kreiswirth, B.N., Musser, J.M. and DeLeo, F.R., (2005).** Insights into mechanisms used by *Staphylococcus aureus* to avoid destruction by human neutrophils. *Journal of Immunology*, **175**:3907–3919.

**Wang, R., Gao, Y. and Lai, L. (2000).** LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design, *Journal of Molecular Modeling*, **6**:498-516.

**Ward, P.D. and Turner, W.H. (1980).** Identification of staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. *Infection and Immunity*, **28**:393–397.

**Wertheim, H.F., Melles, D.C., Vos, M.C., van Leeuwen, W., van Belkum, A., Verbrugh, H.A. and Nouwen, J.L. (2005).** The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infectious Diseases*. **5**:751–762.

**Wiederstein, M. and Sippl, M.J. (2007).** ProSA-web:interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Research*, **35**:407- 410.

**Williams, R.E. (1963).** Healthy carriage of *Staphylococcus aureus*: its prevalence and importance. *Bacteriological Reviews*, **27**:56–71.

**Yadav, P.K., Singh, G., Gautam, B., Singh, S., Yadav, M., Srivastav, U. and Singh, B. (2013).** Molecular modeling, dynamics studies and virtual screening of Fructose 1, 6 biphosphate aldolase-II in community acquired- methicillin resistant *Staphylococcus aureus* (CA-MRSA). *Bioinformation*, **9**:158-164.

**Yadav, P.K., Singh, G., Singh, S., Gautam, B. and Saad, E.I.F. (2012).** Potential therapeutic drug target identification in Community Acquired-Methicillin Resistant *Staphylococcus aureus* (CA-MRSA) using computational analysis. *Bioinformation*, **8**:664-672.

**Yadav, P.K., Singh, S., Seniya, C., Singh, A.K. and Khan, G.J. (2011).** Structure based drug design approaches in drug discovery. In: Dhingra, H. *et al.* (editors). *Current topics in Biotechnology and Microbiology*. 1<sup>st</sup> edition, Lap Lambert Academic Publishing AG & CO. KG Dudweiler Landstr, Germany, pp 178-195.

**Yu, N.Y., Wagner, J.R., Laird, M.R., Melli, G., Rey, S., Lo, R., Dao, P., Sahinalp, S.C., Ester, M., Foster, L.J., Brinkman, F.S. (2010).** PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. *Bioinformatics*. **26**:1608-1615.

**Zeng, J. (2000).** Computational structure-based design of inhibitors that target protein surfaces. *Combinatorial Chemistry and High Throughput Screening*, **3**:355-362.

**Zetola, N., Francis, J.S., Nuermberger, E.L. and Bishai, W.R. (2005).** Community-acquired methicillin-resistant *Staphylococcus aureus*: An emerging threat. *Lancet Infectious Diseases*, **5**:275–286.

**Zhang, R. and Lin, Y. (2009).** DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. *Nucleic Acids Research*, **37**:D455-D458.

**Zhang, Z., Li, Y., Lin, B., Schroeder, M. and Huang, B. (2011).** Identification of cavities on protein surface using multiple computational approaches for drug binding site prediction. *Bioinformatics*, **27**:2083-2088.

**Zoraghi, R., See, R.H., Axerio-Cilies, P., Kumar, N.S., Gong, H., Moreau, A., Hsing, M., Kaur, S., Swayze, R.D., Worrall, L., Amandoron, E., Lian, T., Jackson, L., Jiang, J., Thorson, L., Labriere, C., Foster, L., Brunham, R.C., McMaster, W.R., Finlay, B.B., Strynadka, N.C., Cherkasov, A., Young, R.N. and Reiner, N.E. (2011).** Identification of pyruvate kinase in methicillin-resistant *Staphylococcus aureus* as a novel antimicrobial drug target. *Antimicrobial Agents and Chemotherapy*, **55**:2042-2053.